Latest Percheron Therapeutics (ASX:PER) News
Page 3
Page 3 of 3
Percheron Therapeutics Reports $14.9M Loss, Shifts Focus to Promising Oncology Asset
28 Aug 2025
Percheron Secures Phase II-Ready Cancer Drug, Eyes 2026 Trials
31 July 2025
Percheron Secures Exclusive License for Phase II-Ready Cancer Drug HMBD-002
26 June 2025
Percheron Therapeutics Cuts ATL1103, Limits ATL1102 Spend, Eyes New Rare Disease Assets
30 Apr 2025
Percheron Halts Avicursen Trial, Raises $14.85M to Pivot Pipeline Strategy
31 Jan 2025